Biotech not discouraged by Merck protease inhibitor setback

Biotech not discouraged by Merck protease inhibitor setback

The biotech contenders in the HIV protease inhibitor race haven't been discouraged by recent reports that virus levels in patients treated with Merck's L-735,524 compound have returned to baseline levels.

Merck's problems with its lead compound were totally predictable,

Read the full 472 word article

How to gain access

Continue reading with a
two-week free trial.